ZETAMET™ BONE GRAFT IN THE REPAIR OF BONE DEFECTS FROM METASTATIC BREAST CANCER IN VERTEBRAL BONES

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Metastatic Breast Cancer in the Spine

Interventions

COMBINATION_PRODUCT

ZetaMet™ (ZetaFuse™ Bone Graft)

ZetaMet™ (ZetaFuse™ Bone Graft) will be percutaneously implanted into the vertebral body defect(s) created by the lytic metastatic tumor.

Trial Locations (2)

Vancouver Coastal Health Research Institute, Vancouver

McGill University Health Center, Montreal

All Listed Sponsors

lead

Zetagen Therapeutics, Inc

INDUSTRY